Global Human Respiratory Syncytial Virus Drugs Market Trends and Forecasts 2016-2020

Report : Global Human Respiratory Syncytial Virus Drugs Market 2016-2020 is a new market research publication announced by Reportstack. 

Report Outline: Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

For detailed report with TOC, please click here ​Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Market Growth: The global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Key vendors • AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical

Other prominent vendors • Ablynx 
• ADMA Biologics
• Alnylam Pharmaceuticals
• Ark Biosciences
• Aviragen Therapeutics
• Bavarian Nordic
• Boehringer Ingelheim 
• Gilead Sciences
• ImmunoVaccine Technologies
• Johnson & Johnson
• Kyowa Hakko Kirin
• Medivir
• Mucosis
• Mymetics Corporation 
• Novavax
• Regeneron Pharmaceuticals
• ReViral
• Vaxart

Regions Covered:

• Europe
• ROW
• US

Companies Mentioned

Other Prominent Vendors in the market are: Askon Engineers, Bio JetDrier, HOKWANG INDUSTRIES, Taishan Jieda Electrical Industrial, Panasonic, and Palmer Fixture.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###